Evidence map›Paper›PMID 40960686›Full record

ArticleMolecular biology reports2025

Mutant soluble Interleukin-6 receptor as a potential agent for inhibiting cell migration and inducing apoptosis in a breast cancer cell line.

Maryam Sadat Mousavizadeh-Marvast, Mina Mirian, Fatemeh Shafiee

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maryam Sadat Mousavizadeh-MarvastDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Mina MirianDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh ShafieeDepartment of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. f_shafiee@pharm.mui.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesInterleukin-6 (IL-6) plays a crucial role in regulating of survival, invasion, and cell cycle of breast cancer cells. So, it appears that the suppression of IL-6 may function as a potential therapeutic agent in the context of cancer treatment. The aim of the present study is to investigate the effect of a mutated form of the soluble IL-6 receptor (mIL-6R) on the invasive ability and induction of apoptosis in MDA-MB-231 cancer cells.

methodsmIL-6R was expressed and purified in E. coli BL21 (DE3) bacteria and IMPACT system, respectively. The cytotoxic effects, inhibition of cell migration and apoptosis induction of mIL-6R were evaluated using MTT Assay, Scratch Assay, and Flow Cytometry assay, respectively, on the MDA-MB-231 cell line.

resultsAt a concentration of IC50 (7.41 µg.mL

conclusionIt appears that mIL-6R can act as a therapeutic candidate for breast cancer, but further investigations in animal models and clinical trials are required to determine the optimal dose and long-term effects.

Indexed as

ApoptosisBreast NeoplasmsReceptors, Interleukin-6Cell CycleCell Line, TumorCell Migration InhibitionCell MovementCell ProliferationFemaleHumansInterleukin-6MutationIL6R protein, humanInterleukin-6Receptors, Interleukin-6Breast cancerInterleukin-6MDA-MB-231 cell lineMIL-6R

Identifiers

PMID40960686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.